Isomab is developing an antibody treatment for Peripheral Vascular Disease based on the team’s breakthrough discovery in VEGF-A biology. The treatment has the potential to transform the lives of thousands of people living disease.
Total raised: $9.46M
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.02.2024 | - | $9.46M | - |
Mentions in press and media 6
| Date | Title | Description |
| 21.02.2024 | IsomAb: A Beacon of Hope for Diabetic Peripheral Arterial Disease | IsomAb, a biopharmaceutical company based in Nottingham, UK, has secured a significant £7.5 million in funding to advance its groundbreaking treatment for diabetic peripheral arterial disease (PAD). Led by CEO Jackie Turnbull, IsomAb focuse... |
| 20.02.2024 | IsomAb Raises £7.5M in Funding | IsomAb CEO Jackie Turnbull IsomAb, a Nottingham, UK-based biopharmaceutical company, raised £7.5M in funding. The round was led by Broadview Ventures with participation from MEIF Proof of Concept & Early Stage Fund, which is managed by ... |
| 20.02.2024 | IsomAb secures £7.5M for treatment of diabetic peripheral arterial disease | Today IsomAb — a University of Nottingham spin-out pioneering a new treatment for people with diabetes at risk of amputation — has raised £7.5 million in funding. The company focuses on treating peripheral arterial disease (PAD). In this re... |
| 14.09.2023 | SCVC's new fund to propel Pre-Seed and Seed stage tech innovation | Early-stage deep tech investor SCVC, has announced the first close of its second fund, with a target of up to $100 million. The Bristol-based firm invests in advanced technologies to improve the health of people and the planet - from biotec... |
| - | IsomAb | “Home | IsomAb ” |
| - | IsomAb Closes £7.5 Million To Develop Isoform-Specific Disease Modifying Antibody Treatment | IsomAb Ltd – a UK-based biotechnology company – announced today the closing of a £7.5 million (approximately US$9.4 million) Seed financing round, led by Broadview Ventures, with further backing from existing investor, SCVC and participatio... |